Tagged with Exclusive

Pharma With over 15 years of expertise in external sterilization services for medical devices and surgical instruments, Sterience has successfully positioned itself as the market leader in France. Directing the company towards new growth potential, recently appointed CEO, Mr. Jacques Penicaud, shares the company’s commitment to quality, as well as new…

Pharma Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015 Global Innovation Index. For the healthcare sector, the country’s innovation is notably propelled by a myriad of local success-stories, and…

Pharma In keeping with its reputation as a forerunner, the Dutch healthcare eco-system is currently reinventing itself to ensure it remains ahead of the game in terms of both innovation and excellence. Market and patient access, transparency, cost-effectiveness and process innovation all feature prominently as industry and government alike band together…

Pharma The Netherlands is clearly a fertile environment for its 2,200 life science and medtech companies. However, the Dutch ambition to be a frontrunner in new healthcare challenges also comprises an overall approach to treating patients. Aging population, chronic disease, and innovative pharmaceutical treatments’ role in extending patients’ life expectancies have…

Pharma Boston Scientific is raising the bar for medical devices and services in the field of cardiology and other pathologies, including Rhythm Management, Endoscopy, Urology Pelvic Health, and Neurostimulation. European President Eric Thépaut shares why Europe has been dubbed the company’s “growth lab”. Boston Scientific has positioned itself to pave the…

Pharma Vygon CEO, Stephane Regnault, shares the international strategy of one of the largest independent French medical device companies and their continuing commitment to quality. You are one of the few mid-sized French medical device companies thriving on the market. What is the niche market of Vygon, and the evolution of the…

Pharma The Director-General of the Gustave Roussy Institute, a top cancer institute in Europe, talks about the revamping of their clinical research infrastructure to adapt to the rising new field of translational research and his ambitious plans for the next five years, in particular, his vision for Cancer Core Europe, positioned…

Pharma Anne-Marie Noir discusses footcare, Laboratoires Asepta’s corporate values, the strategic development behind their innovative brand, and the company’s positioning in Monaco. She also discusses her family’s legacy in the business and her influence as a powerful woman in a male-dominated industry. Laboratories Asepta has been a very successful company in…

Pharma Mr. Aldo Braca discusses the competitive CDMO landscape in Italy, the importance of nurturing a community of employees, and the optimistic growth trend for the company powered by investment and innovation. This year, BSP celebrated its ten-year anniversary, congratulations! What were the key objectives that you have accomplished since the…

Pharma The pharmaceutical industry needs to work harder to demonstrate the value that it delivers to society and to the greater economy by advancing public health outcomes, delegates at the 14th annual eyeforpharma conference in Barcelona have been told. Addressing over a thousand industry stakeholders at Barcelona’s Centre Convencions Internacional, senior…

Pharma Carlos Jaime, Head of Samsung’s Health & Medical Equipment Division, France, explains why the future of healthcare is in mobile technology and communications, and how Samsung’s expertise in “digital transformations” position the company as a catalyst for change in the industry. The mobile health solution industry is clearly a major…

Pharma In part II of an exclusive interview at the eyeforpharma Barcelona Summit 2016, IMS Health’s Chief Digital Officer Richie Etwaru lifts the lid on the concept of Orchestrated Customer Engagement (OCE) and explains how it can demonstrably advance the ideals of patient centrality, inter-stakeholder trust and industry-wide operability. You have been pioneering…